Read about the project's achievements in the public summary of the project's final report.
FACTS & FIGURES
IMI1 - Call 1
|Grant agreement number||
Type of Action:
11 009 715
|EFPIA in kind||
10 864 491
6 743 176
28 617 382
Achievements & News
Article highlights PROTECT’s impact on regulatory science and practice
The impacts of IMI’s PROTECT project on regulatory science and practice are spelt out in a new paper by project coordinator Xavier Kurz of the European Medicines Agency (EMA), published in the journal Pharmacoepidemiology and Drug Safety. One area where the project made an important difference in regulatory practice is in signal detection, through which medicines ###regulators gather information on suspected adverse drug reactions (ADRs). Based on PROTECT work, changes were made in the tools and processes used for signal detection in the EU database of reports of suspected ADRs. These changes have improved the signal detection process, with fewer false positives and more validated signals. Another area where the project has had an impact is in pharmacoepidemiology, which is the study of the use and effects of medicines in large numbers of people. According to Xavier Kurz, PROTECT’s recommendations in this area will help to improve the quality and consistency of studies, increase confidence in the results of observational studies, and strengthen regulatory decision-making. Benefit-risk assessment was another area where PROTECT delivered results, including a framework for benefit-risk assessment, greater understanding of the use of patient preferences for decision-making, and a website with training material on the subject. These deliverables also provide foundations for further methododological developments in this field. Finally, PROTECT carried out preliminary research on using the internet as a data collection tool.
PROTECT project’s legacy on assessing benefits and risks of medicines
One of IMI’s first projects, PROTECT was set up to develop innovative methods for monitoring the benefits and risks of medicines. Although the project is over, its legacy lives on in the knowledge and tools generated by the project, many of which are presented in a special issue of the journal Pharmacoepidemiology and Drug Safety and a short report published### by the European Medicines Agency (EMA), which coordinated the project. ‘PROTECT has made a significant contribution to the body of scientific knowledge of benefit-risk monitoring methodologies,' said Peter Arlett, Head of the EMA’s Pharmacovigilance department. ‘Results are being implemented into routine pharmacovigilance and regulatory practice. They have already started to improve day-to-day medicines monitoring operations of regulators and pharmaceutical companies, for better safety of European patients.’
Highlights from the project include:
- Good Signal Detection Practice was integrated into tools and regulatory guidance for national authorities and companies.
- Recommendations for observational studies on medicines were integrated into scientific guidance and will be integrated into regulatory practice.
- Recommendations for benefit-risk assessment methodologies and visual representations have led to initiatives that explore practical application of harmonised methods and the involvement of patients and the wider public in the assessment of benefits and risks of medicines.
- Exploring new methods to collect data directly from patients, including via the internet.
- A specific PROTECT benefit-risk website.
- 72 articles in peer-reviewed scientific journals, 14 doctoral theses and 3 master theses.
PROTECT project’s benefit risk assessment advice published
The PROTECT project’s overarching recommendations on the assessment and visualisation of the benefits and risks of medicines have been published in the journal Pharmacoepidemiology and Drug Safety. Evaluating the balance between the benefits and risks of drugs is challenging.### The assessment methodologies and visual representation tools may facilitate benefit-risk assessments. The newly-published paper explains how the project’s recommendations are based on a number of case studies using real medicines. ‘Adopting formal, structured approaches to benefit–risk assessment was feasible in real-world problems and facilitated clear, transparent decision-making,’ the researchers write. ‘Prior to this work, no extensive practical application and appraisal of methodologies had been conducted using real-world case examples, leaving users with limited knowledge of their usefulness in the real world. The practical guidance provided here takes us one step closer to a harmonised approach to benefit–risk assessment from multiple perspectives.’
Details of the PROTECT project’s output can be found on the project’s website.
Catch up on previous IMI project events
If you missed some recent IMI project events, you can catch up online! Presentations and video recordings from the Final Symposium Training of the PROTECT are now available online. ###The material covers:
- the main concepts of benefit-risk assessment,
- a range of methodologies used in connection with benefit-risk assessment,
- key methodologies via worked examples,
- a range of visual representations to accompany benefit-risk assessment and
- a selection of visual displays via worked examples, and the role of patient and public involvement in benefit-risk assessment
Also available for download are the materials from the recent LifeTrain workshop. Claire Johnson of EMBL, who was the head of this year’s workshop programme committee concluded after the event that ‘with the 2015 LifeTrain workshop we have made yet another significant step in creating awareness for education and training in biomedical research among the very heterogeneous group of signatories, supporters and friends….’ A summary of the conclusions, presentations, agenda, photos and posters from the LifeTrain workshop are now available online.
PROTECT benefit / risk website goes live
IMI’s PROTECT project has launched a new website showcasing its work on ways of assessing and visualising the benefits and risks of medicines.### The evaluation of the balance between the benefits and risks of drugs is fundamental to numerous stakeholders including patients, healthcare providers, health technology assessors, regulators and pharmaceutical companies. Decision-making with regards to benefit-risk assessment is often complex. It is important to ensure transparent, robust and comprehensive methodologies are used, and also that patient and public preferences on benefits and risks feed into the decision-making process. To achieve these goals, the PROTECT Benefit-Risk group has developed a clear set of practical recommendations for benefit-risk decision processes and supporting tools, which the project hopes will serve as a valuable guide for people who are new to the world of benefit-risk assessment. These recommendations highlight key issues and considerations that are common to many approaches and benefit-risk decision problems.
PROTECT survey to improve communication of benefits & risks
IMI’s PROTECT project is running a survey that will feed into efforts to improve the way the benefits and risks of medicines are communicated to patients and health professionals alike.### All medicines come with both benefits and risks, and understanding the balance between these is essential when making treatment decisions. Benefits and risks can be communicated in diverse ways, including written texts and different kinds of graphics. The PROTECT survey sets out different ways of presenting benefits and risks and asks which are best for making treatment decisions. The project has designed different surveys for patients, healthcare professionals, and those responsible for assessing medicines in three areas: breast cancer, diabetes, and atrial fibrillation. It takes 30-65 minutes to complete, depending on the disease area. No personal identifying information is collected and all answers are kept confidential
Updates of the Drug Consumption Databases published
IMI’s PROTECT project has published an updated version of the Drug Consumption Databases – a comprehensive and structured source of information on drug consumption in the out- and inpatient healthcare sector in Europe.###
The databases consist of two documents: a master document containing a detailed account of the information already available and methods to retrieve it and a country profile document summarising by country information on national health systems, reimbursement characteristics and a list of websites of interest. The databases contain information for the following countries: Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Norway, Poland, Portugal, Slovenia, Spain, Sweden, the Netherlands, and the United Kingdom.
All interested readers are encouraged to review and comment on the two documents as they are a shared source among researchers, regulatory agencies, and pharmaceutical companies.
PROTECT releases reviews of benefit - risk methods and their visualisation
IMI project PROTECT has published reviews of the available methodologies for the assessment, integration and visualisation of the risks and benefits of medicines.### The project team analysed a wide range of methodologies for assessing the benefits and risks of medicines; the report on this shows the links between different methods and groups them. Finally, the report sets out recommendations on the methods that merit further consideration for decision-making on medicines in different contexts. These methods will be explored further in the next stage of the PROTECT project.
PROTECT also analysed different ways of visualising benefits and risks. The report presents visual representations that could be associated with the 13 benefit-risk methodologies recommended in the benefit-risk methodology review, assesses their suitability and offers recommendations for suitable visuals for each benefit-risk assessment approach.
- Both reports, along with a number of case studies, can be found online
PROTECT project releases major pharmacovigilance databases
IMI’s PROTECT project has published two key databases for pharmacovigilance on its website. The inventory of Drug Consumption Databases in Europe provides a comprehensive and structured source of information on drug consumption in Europe###, while the PROTECT ADR database is a downloadable Excel file listing all adverse drug reactions (ADRs) listed in the Summary of Product Characteristics (SPC) of medicinal products authorised in the EU. ‘We hope that these databases will represent useful resources for the scientific community and for regulatory and public health authorities,’ said PROTECT project coordinator Xavier Kurz of the European Medicines Agency (EMA).
Pregnant women needed for PROTECT survey on medicines use in pregnancy
Elsewhere, the PROTECT team has launched a major, four-country survey on drug use by pregnant women. Although automated systems can find out what medicines have been prescribed for pregnant women###, they do not provide information on whether or not the patient actually took the drugs, and they do not cover medicines bought over the counter or herbal and homeopathic remedies. By gathering detailed data on pregnant women’s actual medicine intake, as well as information on lifestyle factors, the PROTECT project hopes to be able to improve the advice given to pregnant women and so make pregnancies safer.
Participants Show participants on map
- Amgen, Brussels, Belgium
- Astrazeneca AB, Södertälje, Sweden
- Bayer Pharma AG, Berlin, Germany
- Eli Lilly and Company Limited, Basingstoke, United Kingdom
- F. Hoffmann-La Roche AG, Basel, Switzerland
- Genzyme Europe B.V., Naarden, Netherlands
- Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
- H. Lundbeck As, Valby, Denmark
- Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
- Novartis Pharma AG, Basel, Switzerland
- Novo Nordisk A/S, Bagsvaerd, Denmark
- Pfizer Limited, Sandwich, Kent , United Kingdom
- Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
- Takeda Development Centre Europe LTD, London, United Kingdom
Universities, research organisations, public bodies, non-profit groups
- Aarhus Universitet, Aarhus C, Denmark
- Academisch Ziekenhuis Groningen, Groningen, Netherlands
- Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain
- Department of Health, Leeds, United Kingdom
- Fundacio' Institut Català de Farmacologia, Barcelona, Spain
- Fundación Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain
- Imperial College Of Science Technology And Medicine, London, United Kingdom
- Institut National De La Sante Et De La Recherche Medicale, Paris, France
- Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy
- Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
- Private Universitaet Witten/Herdecke gGmbH, Witten, Germany
- Rijksuniversiteit Groningen, Groningen, Netherlands
- Stiftelsen WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
- The European Medicines Agency, Canary Wharf, London, United Kingdom
- Universiteit Utrecht, Utrecht, Netherlands
- University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom
- Uniwersytet Medyczny Im Karola Marcinkowskiego W Poznaniu, Poznan, Poland
Small and medium-sized enterprises (SMEs)
- L.A Sante, Epidemiologie, Evaluation Et Recherche L.A.S.E.R., Paris, France
- Outcome Europe Sarl, St. Prex, Switzerland
- International Alliance of Patients’ Organizations, London, United Kingdom
- Institut Catala De La Salut, Barcelona, Spain
- Quintiles Benefit France Inc, Levallois Perret, France
- Quintiles Limited, Reading, United Kingdom
Non EFPIA companies
- Lægemiddelstyrelsen, Copenhagen S, Denmark
|Name||IMI funding in €|
|Aarhus Universitet||322 087|
|Academisch Ziekenhuis Groningen||268 604|
|Agencia Espanola De Medicamentos Y Productos Sanitarios||374 520|
|Department of Health||492 896|
|Fundacio' Institut Català de Farmacologia||622 643|
|Fundación Centro Español de Investigación Farmacoepidemiológica||280 450|
|Imperial College Of Science Technology And Medicine||767 316|
|Institut National De La Sante Et De La Recherche Medicale||539 760|
|International Alliance of Patients’ Organizations||116 294|
|Istituto Di Ricerche Farmacologiche Mario Negri||232 500|
|L.A Sante, Epidemiologie, Evaluation Et Recherche L.A.S.E.R.||1 400 657|
|Ludwig-Maximilians-Universitaet Muenchen||346 803|
|Outcome Europe Sarl||983 677|
|Private Universitaet Witten/Herdecke gGmbH||38 820|
|Rijksuniversiteit Groningen||329 741|
|Stiftelsen WHO Collaborating Centre for International Drug Monitoring||1 013 796|
|The European Medicines Agency||396 258|
|Universiteit Utrecht||1 428 695|
|University Of Newcastle Upon Tyne||244 890|
|Uniwersytet Medyczny Im Karola Marcinkowskiego W Poznaniu||57 014|
|Total Cost||11 009 715|